Business
GMT: Losses persist as Genomtec advances R&D, secures funding, and pursues M&A for commercialisation
GMT: Losses persist as Genomtec advances R&D, secures funding, and pursues M&A for commercialisation
About this update from Genomtec Sa
Genomtec reported continued losses in Q3 2024 as it advances its Genomtec ID and oncology projects, relying on grants and a recent share issue for funding. M&A discussions and patent grants marked key developments, with commercialisation still pending.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.